Search research articles
Contact Us
Filters
Showing results (101-110 of 222) with videos related to
Page
of 23
Sort By:
The British Journal of Dermatology
|
February 10, 2023
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3
Kristian Reich, Eric Simpson, Andreas Wollenberg, et al.
Experimental Dermatology
|
October 18, 2018
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition
Emma Guttman-Yassky, Jon M Hanifin, Mark Boguniewicz, et al.
European Journal of Dermatology : EJD
|
October 27, 2022
Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
Andreas Wollenberg, Peter Lio, Elise Kleyn, et al.
Journal of Cutaneous Medicine and Surgery
|
November 22, 2017
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition
Robert Bissonnette, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery
|
May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004
Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Biomolecules
|
February 25, 2023
NOD2 Agonism Counter-Regulates Human Type 2 T Cell Functions in Peripheral Blood Mononuclear Cell Cultures: Implications for Atopic Dermatitis
Vladimir-Andrey Gimenez-Rivera, Harshita Patel, Franck P Dupuy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 1, 2023
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI)
A David Burden, Robert Bissonnette, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
April 24, 2023
Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study
Pablo A Jimenez, Howard L Sofen, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 7, 2010
Redefining treatment options in chronic hand eczema (CHE)
Robert Bissonnette, Thomas L Diepgen, Peter Elsner, et al.
Journal of the American Academy of Dermatology
|
February 21, 2006
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis
Robert Bissonnette, Kim Papp, Yves Poulin, et al.
Page
of 23
Search research articles
Search
Showing results (101-110 of 222) with videos related to
Sort By:
Page
of 23
The British Journal of Dermatology
|
February 10, 2023
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3
Kristian Reich, Eric Simpson, Andreas Wollenberg, et al.
Experimental Dermatology
|
October 18, 2018
The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition
Emma Guttman-Yassky, Jon M Hanifin, Mark Boguniewicz, et al.
European Journal of Dermatology : EJD
|
October 27, 2022
Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
Andreas Wollenberg, Peter Lio, Elise Kleyn, et al.
Journal of Cutaneous Medicine and Surgery
|
November 22, 2017
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition
Robert Bissonnette, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery
|
May 4, 2005
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004
Lyn Guenther, Richard G Langley, Neil H Shear, et al.
Biomolecules
|
February 25, 2023
NOD2 Agonism Counter-Regulates Human Type 2 T Cell Functions in Peripheral Blood Mononuclear Cell Cultures: Implications for Atopic Dermatitis
Vladimir-Andrey Gimenez-Rivera, Harshita Patel, Franck P Dupuy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
March 1, 2023
Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI)
A David Burden, Robert Bissonnette, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
April 24, 2023
Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study
Pablo A Jimenez, Howard L Sofen, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
May 7, 2010
Redefining treatment options in chronic hand eczema (CHE)
Robert Bissonnette, Thomas L Diepgen, Peter Elsner, et al.
Journal of the American Academy of Dermatology
|
February 21, 2006
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis
Robert Bissonnette, Kim Papp, Yves Poulin, et al.
Page
of 23